Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-Nipah Virus vaccine
- Development stage
- Preclinical
- Lead developer
- Gennova Biopharmaceuticals
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
mRNA-Nipah Virus vaccine is an investigational mRNA-based vaccine developed by Vernagen for the prevention of Nipah virus infection. The vaccine utilizes mRNA technology to instruct host cells to synthesize Nipah virus antigens, which then elicit a protective immune response. As of early 2024, the vaccine is in the preclinical stage, specifically undergoing animal efficacy testing in collaboration with Duke-NUS Medical School in Singapore. This candidate is part of Vernagen's broader mRNA vaccine pipeline targeting emerging infectious diseases and utilizes a platform designed to provide rapid response capabilities against viral pathogens.
- Other names
- mRNA-Nipah Virus vaccineVernagen Nipah vaccine
02
Targets
NiV (Nipah virus)
Beyond the preview
Go deeper on mRNA-Nipah Virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-Nipah Virus vaccine.